BBA
STML

Baker Bros. Advisors’s Stemline Therapeutics, Inc. STML Stock Holding History

Baker Bros. Advisors’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-44,524
Closed -$715K – 123
2018
Q2 		$715K Sell
44,524
-243,303
-85% -$4.34M 0.01% 112
2018
Q1 		$4.4M Sell
287,827
-345,670
-55% -$5.39M 0.04% 80
2017
Q4 		$9.88M Hold
633,497
– – 0.09% 57
2017
Q3 		$7.03M Hold
633,497
– – 0.06% 67
2017
Q2 		$5.83M Hold
633,497
– – 0.05% 62
2017
Q1 		$5.42M Buy
633,497
+300,000
+90% +$2.73M 0.04% 64
2016
Q4 		$3.57M Hold
333,497
– – 0.04% 71
2016
Q3 		$3.61M Hold
333,497
– – 0.03% 74
2016
Q2 		$2.26M Hold
333,497
– – 0.02% 96
2016
Q1 		$1.55M Hold
333,497
– – 0.02% 106
2015
Q4 		$2.1M Hold
333,497
– – 0.02% 104
2015
Q3 		$2.94M Hold
333,497
– – 0.03% 91
2015
Q2 		$3.92M Hold
333,497
– – 0.03% 84
2015
Q1 		$4.83M Sell
333,497
-5,174
-2% -$79.2K 0.04% 76
2014
Q4 		$5.78M Hold
338,671
– – 0.06% 69
2014
Q3 		$4.22M Hold
338,671
– – 0.05% 67
2014
Q2 		$4.97M Hold
338,671
– – 0.06% 70
2014
Q1 		$6.89M Sell
338,671
-336,371
-50% -$8.16M 0.09% 59
2013
Q4 		$13.2M Sell
675,042
-125,358
-16% -$3.35M 0.19% 43
2013
Q3 		$36.3M Sell
800,400
-99,600
-11% -$3.25M 0.52% 24
2013
Q2 		$21.5M Buy
+900,000
New +$14.3M 0.42% 25

Other funds holding STML

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Baker Bros. Advisors's STML Position: Q3 2018 in Review

Baker Bros. Advisors sold out of Stemline Therapeutics, Inc. (STML) in Q3 2018, closing a stake of 44,524 shares — an estimated $715K sold.

Baker Bros. Advisors first reported a position in STML in Q2 2013 and held it in 21 quarters. The position peaked at $36.3M in Q3 2013. 90 funds tracked by Wall St. Rank hold STML as of Q3 2018.

  • Baker Bros. Advisors reported no remaining Stemline Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
  • Baker Bros. Advisors sold 44,524 Stemline Therapeutics, Inc. shares in Q3 2018, an estimated $715K.
  • Baker Bros. Advisors first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 21 quarters.
  • Baker Bros. Advisors's Stemline Therapeutics, Inc. position peaked at $36.3M in Q3 2013.
  • 90 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2018.

Based on Baker Bros. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.